AffyXell Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 11

AffyXell Therapeutics General Information

Description

Developer of the next generation of cell and gene therapies intended to treat inflammatory and autoimmune diseases and prevent organ transplant rejection. The company's therapies develop mesenchymal stem cells (MSCs), which are promising agents for the treatment of autoimmune and inflammatory diseases and are intended for therapeutic purposes, enabling health professionals to provide proper treatment for various diseases.

Contact Information

Website
affyxell.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 404, Gimhae Biomedical Industry Promotion Agency Techno Town
  • 80-59, Golden Route-ro, Juchon-myeon
  • Gimhae, Gyeongsangnam
  • South Korea
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Room 404, Gimhae Biomedical Industry Promotion Agency Techno Town
  • 80-59, Golden Route-ro, Juchon-myeon
  • Gimhae, Gyeongsangnam
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AffyXell Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 16-May-2022 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Feb-2021 Completed Generating Revenue
1. Joint Venture 08-Jan-2020 Completed Startup
To view AffyXell Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

AffyXell Therapeutics Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 16

    Pending

  • Expiring in next 12 mo

AffyXell Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026089556-A1 Extracellular vesicles comprising stefin a protein variant specifically binding to target, and uses thereof Pending 25-Oct-2024
JP-2025069065-A Genetically modified cells comprising nucleic acid encoding tnfr2 binding agent and uses thereof Pending 29-Sep-2023
WO-2024201144-A1 Genetically modified cells comprising a nucleic acid encoding a tnfr2 binding agent and uses thereof Inactive 31-Mar-2023
EP-4689072-A1 Genetically modified cells into which a nucleic acid encoding a stefin a protein variants specifically binding to tnfr2 or a fusion protein comprising the same has been introduced, and uses thereof Pending 31-Mar-2023
WO-2024204896-A1 Genetically modified cells into which a nucleic acid encoding a stefin a protein variants specifically binding to tnfr2 or a fusion protein comprising the same has been introduced, and uses thereof Inactive 31-Mar-2023 C12N5/0662
To view AffyXell Therapeutics’s complete patent history, request access »

AffyXell Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AffyXell Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Korea Development Bank VC-Backed Company Minority
ProBio (Drug Discovery) VC-Backed Company Minority
Gyeongnam Venture Investment Venture Capital Minority
Kolon Investment Venture Capital Minority
Samsung Venture Investment Corporate Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

AffyXell Therapeutics FAQs

  • When was AffyXell Therapeutics founded?

    AffyXell Therapeutics was founded in 2020.

  • Where is AffyXell Therapeutics headquartered?

    AffyXell Therapeutics is headquartered in Gimhae, South Korea.

  • What is the size of AffyXell Therapeutics?

    AffyXell Therapeutics has 16 total employees.

  • What industry is AffyXell Therapeutics in?

    AffyXell Therapeutics’s primary industry is Drug Discovery.

  • Is AffyXell Therapeutics a private or public company?

    AffyXell Therapeutics is a Private company.

  • What is AffyXell Therapeutics’s current revenue?

    The current revenue for AffyXell Therapeutics is .

  • How much funding has AffyXell Therapeutics raised over time?

    AffyXell Therapeutics has raised $7.3M.

  • Who are AffyXell Therapeutics’s investors?

    Korea Development Bank, ProBio (Drug Discovery), Gyeongnam Venture Investment, Kolon Investment, and Samsung Venture Investment are 5 of 11 investors who have invested in AffyXell Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process